top of page
alectinib_banner.jpg

Home / Information / Alectinib

Alectinib

Alectinib is a 2nd generation TKI developed by Roche. The recommended dose is 600mg taken twice daily.

Documents

Name

Summary of Contents

Action

Alectinib and Diets

This webpage contains information on whether your diet has a big effect on common lung cancer treatment.

View website

Alectinib and Weight Gain

A report about serios weight gain with Alectinib.

View website

Alectinib Dose Reduction

This webpage contains information on Alectinib dose reduction and the side effects caused by reduction.

View website

Alectinib Induced Skin Rash

This document provides information for on patients with high grade Alectinib induced skin rashes.

Download

Safety of Dose Escalation

This document contains information on the safety of dose escalated Alectinib in patients with ALK+ NSCLC.

Download

Image
Image

ALK Positive Lung Cancer (UK) is committed to producing reliable, accurate and up-to-date content reflecting the best available research evidence and best clinical practice. We aim to provide unbiased information free from any commercial conflicts of interest.

​

ALK Positive Lung Cancer (UK) is a registered charity in England and Wales ((1181171) and Scotland (SC053692).  The registered office is at 1 Ethley Drive, Raglan, Monmouthshire, NP15 2FD.

The content of this website is for information only and should not be used for the diagnosis or treatment of medical conditions.  We are unable to offer specific medical advice and, if you are worried about any symptoms, you should consult your doctor.​​

View our privacy policy HERE        View our consent policy HERE

No part of this publication may be reproduced or tansmitted in any form or by any means, electronically, mechanically or manually without permission in writing of ALK Positive Lung Cancer (UK).

bottom of page